Jw Cayman Therapeutics Co
Jw Cayman Therapeutics Co., also known as JW Therapeutics, is a leading biotechnology firm headquartered in China (CN). Founded in 2016, the company has rapidly established itself in the cell therapy industry, focusing on innovative treatments for cancer and other serious diseases. With a strong operational presence in major regions across Asia, JW Therapeutics is committed to advancing the field of immunotherapy. The company’s core offerings include CAR-T cell therapies, which are distinguished by their cutting-edge technology and personalised approach to treatment. JW Therapeutics has achieved significant milestones, including successful clinical trials and partnerships that enhance its market position. Recognised for its commitment to quality and innovation, JW Therapeutics continues to make strides in transforming patient care through advanced therapeutic solutions.
DitchCarbon Score
How does Jw Cayman Therapeutics Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jw Cayman Therapeutics Co's score of 23 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Jw Cayman Therapeutics Co's reported carbon emissions
In 2023, Jw Cayman Therapeutics Co reported total carbon emissions of approximately 4,971,460 kg CO2e, marking a significant reduction from previous years. The breakdown of emissions includes about 88,400 kg CO2e from Scope 1 and approximately 4,883,060 kg CO2e from Scope 2. This represents a continued downward trend in emissions, with a total of about 5,205,130 kg CO2e in 2022 and approximately 5,489,860 kg CO2e in 2021. Despite these reductions, Jw Cayman Therapeutics Co has not publicly committed to specific reduction targets or initiatives, nor have they aligned with the Science Based Targets initiative (SBTi). The company has disclosed emissions data for Scope 1 and Scope 2, but there is no information available regarding Scope 3 emissions or any formal climate pledges. Overall, Jw Cayman Therapeutics Co's emissions data reflects a commitment to reducing their carbon footprint, although further transparency regarding their climate strategies and targets would enhance their sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 74,480 | 000,000 | 00,000 | 00,000 |
| Scope 2 | 5,374,290 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jw Cayman Therapeutics Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
